Philadelphia Power Moves: Spark Therapeutics gets a new CEO
University City Science Center announces 2024 Nucleus Awards honorees and Keystone LifeSci Collaborative chose its first managing director.
Spark Therapeutics
Manufacturing · Pennsylvania, United States · 700 Employees
View Company Info for Free
About
Headquarters
3737 Market St, Philadelphia, Pennsylvania, 191...Phone Number
(215) 220-9300Website
www.sparktx.comRevenue
$236.3 MillionIndustry
Most Recent Scoops
Aug 18 2024
Open Position
Jul 21 2024
Open Position
Highlights
$1B
Total Funding Amount
$110M
Most Recent Funding Amount
7
Number of Funding Rounds
Who is Spark Therapeutics
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its product s include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The companys products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia,...Read more
Spark Therapeutics Org Chart
Is Spark Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Spark Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Spark Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Spark Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Spark Therapeutics
Earning: See what the market has to say on Spark Therapeutics recently announced quarterly report
Product Launch: Get notified when Spark Therapeutics launches new products
Click to see if Spark Therapeutics had a recent Job posting/layoffs
Spark Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Spark Therapeutics as Masked Content
Find more new buyers
Similar Companies to Spark Therapeutics
Analyze insights from companies similar to Spark Therapeutics and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- MeiraGTx402
$11.4M - AskBio859$19.4M
- REGENXBIO344$89M
- bluebird bio323$21.7M
- Sangamo Therapeutics405$12.3M
- Kite Pharma2,000$353.2M
- Ultragenyx1,276$481.3M
- Bridgebio Pharma550$219.1M
More similar companies
Spark Therapeutics financials insights
Gather financial insights about Spark Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Spark Therapeutics Employee Growth Rate
View Spark Therapeutics’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Spark Therapeutics Tech Stack
A closer look at the technologies used by Spark Therapeutics
See more technologies
Most Recent Scoops
Aug 18 2024
Open Position
Aug 16 2024
Open Position
Jul 21 2024
Open Position
Jul 1 2024
Open Position
Jun 25 2024
Open Position
Spark Therapeutics News & Media
Pompe Disease Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Leading Companies - Asklepios Biopharmaceutical, Inc., Astellas Pharma Inc., Amicus Therapeutics, Sanofi, Spark Therapeutics
The expected launch of various emerging therapies along with various approved therapies shall fuel the growth of the Pompe disease market during the forecast period, i.e., 2023–2032. LAS VEGAS, Oct. 26, 2023 /PRNewswire/ -- DelveInsight's Pompe Disease Market Insights report includes a...SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease
SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio's proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed...Spark Therapeutics broke ground on its 500K-square-foot Gene Therapy Innovation Center
And a look at where Philadelphia stands with lab space availability.Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technolog
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Spark Therapeutics
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or... Read More
